Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection

Completed · Not applicable

Conditions studied: HIV Infections

In brief

Examine the ability of thymopentin (Timunox) to: Reduce the amount and/or frequency of virus isolation. Stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.

Key facts

Study ID: NCT00002066
Run by: Immunobiology Research Institute
Last updated by the study team: 2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Concurrent Medication:
Allowed:
Aerosolized pentamidine.
Prior Medication:
Allowed:
Aerosolized pentamidine.

You may not qualify if…

Co-existing Condition:
Patients with an abnormal chest x-ray indicative of active disease (opportunistic infection) within 30 days prior to entry are excluded.
Concurrent Medication:
Excluded within 90 days of study entry:
Zidovudine (AZT).
Prior Medication:
Excluded within 30 days of study entry:
Immunomodulatory or experimental therapy.
Excluded within 90 days of study entry:
Zidovudine (AZT).
Patients must not have:
Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products.
AIDS as defined by the CDC (except for those with HIV "wasting syndrome").
Significant hepatic disease.
Thrombocytopenia (< 75000 platelets/mm3).
Patient must voluntarily sign consent and be seropositive for HIV-1 (ELISA assay) confirmed by Western blot.
HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patient's peripheral blood monocytes (PBMC) on two separate occasions.
Patients with HIV "wasting syndrome" are included.
Intravenous drug abuse.

Where it is running

Immunobiology Research Institute — Annandale, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.